HCID 59596400, 화합물 → HCID 59596404, 화합물
반응식
[F:1][C:2]([F:41])([F:40])[C:3]1[CH:4]=[C:5]([NH:17][C:18]([N:20]2[CH2:26][CH2:25][CH2:24][CH2:23][C:22]3[CH:27]=[C:28]([O:31][C:32]4[CH:37]=[C:36](Cl)[N:35]=[C:34]([NH2:39])[N:33]=4)[CH:29]=[CH:30][C:21]2=3)=[O:19])[CH:6]=[CH:7][C:8]=1[CH2:9][N:10]1[CH2:15][CH2:14][N:13]([CH3:16])[CH2:12][CH2:11]1>CO.[Pd]>[F:41][C:2]([F:1])([F:40])[C:3]1[CH:4]=[C:5]([NH:17][C:18]([N:20]2[CH2:26][CH2:25][CH2:24][CH2:23][C:22]3[CH:27]=[C:28]([O:31][C:32]4[CH:37]=[CH:36][N:35]=[C:34]([NH2:39])[N:33]=4)[CH:29]=[CH:30][C:21]2=3)=[O:19])[CH:6]=[CH:7][C:8]=1[CH2:9][N:10]1[CH2:15][CH2:14][N:13]([CH3:16])[CH2:12][CH2:11]1참가 물질
4
실험 절차
250 mg (0.42 mMol) of 7-(2-amino-6-chloro-pyrimidin-4-yloxy)-2,3,4,5-tetrahydro-benzo[b]azepine-1-carboxylic acid [3-trifluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-phenyl]-amide in 35 ml methanol are hydrogenated in the presence of 160 mg Pd/C (10%; Engelhard 4505). The catalyst is filtered off, the filtrate diluted with EtOAc and sat. Na2CO3/H2O 1:1 and the separated aqueous layer extracted twice with water. The organic layers are washed with water and brine, dried (Na2SO4) and concentrated. Reversed phase MPLC (Gilson system) gives the title compound: MS: [M+1]+=556; HPLC: AtRet=9.0.